EUVIMEDEUVIMED entdecken
Open Access

Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers

William B Feldman, Jerry Avorn, Aaron S Kesselheim, Joshua J Gagne

JAMA Internal Medicine · 2023

DOI: 10.1001/jamainternmed.2023.1245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, 2023. Verfasst von William B Feldman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hos…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Pneumonia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Clinical guidelines on chronic obstructive pulmonary disease (COPD) recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long-acting β-agonists (LABAs) over inhalers containing inhaled corticosteroids (ICSs) and LABAs. However, data from randomized clinical trials comparing these combination inhalers (LAMA-LABAs vs ICS-LABAs) have been conflicting and raised concerns of generalizability.

Objective

To assess whether LAMA-LABA therapy is associated with reduced COPD exacerbations and pneumonia hospitalizations compared with ICS-LABA therapy in routine clinical practice. Design, Setting, and Participants This was a 1:1 propensity score–matched cohort study using Optum’s Clinformatics Data Mart, a large commercial insurance–claims database. Patients must have had a diagnosis of COPD and filled a new prescription for a combination LAMA-LABA or ICS-LABA inhaler between January 1, 2014, and December 31, 2019. Patients younger than 40 years were excluded, as were those with a prior diagnosis of asthma. The current analysis was performed from February 2021 to March 2023. Exposures Combination LAMA-LABA inhalers (aclidinium-formoterol, glycopyrronium-formoterol, glycopyrronium-indacaterol, tiotropium-olodaterol, or umeclidinium-vilanterol) and combination ICS-LABA inhalers (budesonide-formoterol, fluticasone-salmeterol, fluticasone-vilanterol, or mometasone-formoterol). Main Outcome The primary effectiveness outcome was first moderate or severe COPD exacerbation, and the primary safety outcome was first pneumonia hospitalization. Propensity score matching was used to control for confounding between the 2 groups. Logistic regression analysis was used to estimate propensity scores. Hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models stratified on matched pairs.

Results

Among 137 833 patients (mean [SD] age, 70.2 [9.9] years; 69 530 [50.4%] female) (107 004 new ICS-LABA users and 30 829 new LAMA-LABA users), 30 216 matched pairs were identified for the primary analysis. Compared with ICS-LABA use, LAMA-LABA use was associated with an 8% reduction in the rate of first moderate or severe COPD exacerbation (HR, 0.92; 95% CI, 0.89-0.96) and a 20% reduction in the rate of first pneumonia hospitalization (HR, 0.80; 95% CI, 0.75-0.86). These findings were robust across a range of prespecified subgroup and sensitivity analyses.

Conclusion

In this cohort study, LAMA-LABA therapy was associated with improved clinical outcomes compared with ICS-LABA therapy, suggesting that LAMA-LABA therapy should be preferred for patients with COPD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructivePneumoniaHumansFemaleAgedMaleGlycopyrrolateCohort StudiesAdrenergic beta-2 Receptor AgonistsAdministration, InhalationFluticasoneAdrenal Cortex HormonesNebulizers and VaporizersMuscarinic AntagonistsFormoterol FumarateBronchodilator AgentsDrug Therapy, CombinationBenzyl AlcoholsChlorobenzenes

Substanzen

GlycopyrrolateAdrenergic beta-2 Receptor AgonistsFluticasoneAdrenal Cortex HormonesMuscarinic AntagonistsFormoterol FumarateBronchodilator AgentsvilanterolBenzyl AlcoholsChlorobenzenes

Autor:innen und Institutionen

  • Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Harvard Medical School, Boston, Massachusetts.
  • Now with Johnson & Johnson, Cambridge, Massachusetts.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Feldman, W. B., Avorn, J., Kesselheim, A. S., & Gagne, J. J. (2023). Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2023.1245

Vancouver

Feldman WB, Avorn J, Kesselheim AS, Gagne JJ. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers. JAMA Internal Medicine. 2023. doi:10.1001/jamainternmed.2023.1245

BibTeX
@article{Feldman2023,
  author = {Feldman, William B and Avorn, Jerry and Kesselheim, Aaron S and Gagne, Joshua J},
  title = {Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers},
  journal = {JAMA Internal Medicine},
  year = {2023},
  doi = {10.1001/jamainternmed.2023.1245}
}
Kostenlos starten →